Inflammatory bowel disease linked to prostate cancer

December 07, 2018



CHICAGO --- Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.

This is the first report to show men with inflammatory bowel disease have higher than average PSA (prostate-specific antigen) values, and this group also has a significantly higher risk of potentially dangerous prostate cancer.

About 1 million men have inflammatory bowel disease in the U.S. Inflammatory bowel disease is a common chronic condition that includes Crohn's disease and ulcerative colitis.

"These patients may need to be screened more carefully than a man without inflammatory bowel disease," said lead study author Dr. Shilajit Kundu. "If a man with inflammatory bowel disease has an elevated PSA, it may be an indicator of prostate cancer."

Kundu is an associate professor of urology at Northwestern University Feinberg School of Medicine and a Northwestern Medicine physician. He also is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

The study was published in European Urology this week.

In his practice, Kundu sees many men with inflammatory bowel disease who have elevated PSA tests.

"Many doctors think their PSA is elevated just because they have an inflammatory condition," Kundu said. "There is no data to guide how we should treat these men."

For the extensive study, researchers looked at 1,033 men with inflammatory bowel disease and a control group of 9,306 men without the disease. They followed the two groups of men for 18 years and found those with inflammatory bowel disease were much more likely to have prostate cancer and higher PSA levels.

Northwestern scientists are now working to understand the mechanism of how gut inflammation leads to prostate cancer.
-end-
Other Northwestern authors are Jacob A. Burns, Adam B. Weiner, William J. Catalona, Eric V. Li, Edward M. Schaeffer, Stephen B. Hanauer, Scott Strong, James Burns and Maha Hussain.

More News at Northwestern Now
Find experts on our Faculty Experts Hub
Follow@NUSourcesfor expert perspectives
http://news.feinberg.northwestern.edu/tag/press-release/

Northwestern University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.